J. David Enloe, Jr., chief executive officer of Ajinomoto Althea was recently awarded “Most Admired CEO in 2017” by the San Diego Business Journal. Mr. Enloe was recognized for leading Althea through a phase of significant growth and fostering several technical innovation and organizational development initiatives. Under Enloe’s leadership, Althea achieved its highest revenue in its 18 year his­tory in 2016 and has grown its revenues by 25% for the last three years, following the acquisition by Japanese firm, Ajinomoto.
 
Mr. Enloe guided a four-fold increase in the number of manufactured commercial drug products and the company’s expansion into eight countries. He also drove Althea’s entry into the growing oncology field of antibody drug conjugate (ADC) manufacturing, which will enable the company to partner with more cli­ents globally.